immune modulation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-17. Anything still debated is marked as such rather than presented as settled.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Since bandwagoning "requires placing trust in the aggressors continued forbearance" some realists believe balancing is preferred to bandwagoning. According to Stephen Walt, states are more likely to balance in peacetime but if they are on the losing side of a war they may defect and bandwagon in the hopes that they will "share the fruits of victory".
== Professional career == Following her graduation in 1958, Susan Leeman was offered a one-year position as an instructor in the Physiology Department at Harvard Medical School. Realizing she was only a fill-in, the following year she took a job at Brandeis University where she stayed for the next 12 years. During this time she received a Career Development Award which helped her to balance her career and family life. Leeman's research while at Brandeis University mainly focused on the effect a corticotropin-releasing factor (CRF) had on the secretion of adrenocorticotrophic hormone (ACTH) from the anterior pituitary gland. During her effort to purify the CRF, she discovered a peptide that could stimulate the secretion of saliva. This caused her to switch the direction of the project entirely, as she decided to further investigate this peptide. Eventually Leeman and her lab realized she had unintentionally isolated substance P – a peptide originally discovered by Ulf von Euler in the 1930s, but had yet to be chemically defined. Leeman went on to discover the amino acid sequence of substance P and published her findings in the Journal of Biological Chemistry in 1970. During the purification process of substance P, Leeman and a graduate student of hers discovered a different peptide that was distributed throughout the central nervous system, gastrointestinal tract, and immune system, but had yet to be identified. They decided to name their discovery “neurotensin”.
For example, the nitrile group of the competitive PDE-3 inhibitor milrinone forms an affinity-relevant hydrogen bond via a histidine residue located at the binding site of these phosphodiesterases. Nitriles can form a coordinative bond with calcium cations, which is essential for the activity of calcium antagonists of the verapamil type. These agents inhibit calcium influx by forming, through ligand–calcium complex chemistry, a salt bridge with one of the glutamic acid residues in the selectivity filter within the pore of the calcium channel. Verapamil is used in cardiovascular diseases such as arterial hypertension and angina pectoris. Nitrile substituents decrease the electron density of aromatic compounds through a strong inductive effect. In this manner, π-π interactions between a drug molecule and suitable amino acid residues of a target protein, such as phenylalanine, tyrosine, tryptophan, and histidine, are modulated. Such π-π interactions are observed with the aromatase inhibitors letrozole and anastrozole, which act as antiestrogens and are used in breast cancer. Many androgen receptor antagonists contain a markedly electron-deficient aromatic ring, which is particularly important for supramolecular receptor binding. In bicalutamide, enzalutamide, and other analogs used to treat prostate cancer, a nitrile group contributes to this electronic effect. In some cases, nitriles form a reversible yet pharmacologically relevant covalent bond with a target molecule.
Alkyl amines characteristically feature tetrahedral nitrogen centers. C-N-C and C-N-H angles are near 109°. C-N distances are slightly shorter than C-C distances. The energy barrier for the nitrogen inversion of the stereocenter is about 7 kcal/mol for a trialkylamine. The interconversion has been compared to the inversion of an open umbrella into a strong wind. Amines of the type NHRR' and NRR′R″ are chiral: the nitrogen center bears four substituents counting the lone pair. Because of the low barrier to inversion, amines of the type NHRR' cannot be obtained in optical purity. For chiral tertiary amines, NRR′R″ can only be resolved when the R, R', and R″ groups are constrained in cyclic structures such as N-substituted aziridines (quaternary ammonium salts are resolvable).
1989–1991 – 1.3 L (1,323 cc) B3, 1 barrel, 8-valve, 76 PS (56 kW) / 101 N⋅m (74 lb⋅ft) 1991–1994 – 1.3 L (1,323 cc) B3, EGI-S, 8-valve, 79 PS (58 kW) / 103 N⋅m (76 lb⋅ft) 1989–1991 – 1.5 L (1,498 cc) B5-M, carburetor, 16-valve, 91 PS (67 kW) / 122 N⋅m (90 lb⋅ft) 1990–1994 – 1.5 L (1,498 cc) B5-MI, EGI-S, 16-valve 94 PS (69 kW) / 123 N⋅m (91 lb⋅ft) 1989–1991 – 1.5 L (1,498 cc) B5-DE, EFi, 16-valve DOHC, 110 PS (81 kW) / 127 N⋅m (94 lb⋅ft) 1991–1994 – 1.5 L (1,498 cc) B5-DE, EFi, 16-valve DOHC, 115–120 PS (85–88 kW) / 132 N⋅m (97 lb⋅ft) (lower power for AT cars) 1989–1991 – 1.6 L (1,597 cc) B6, 1 barrel, 8-valve, 85 hp (63 kW; 86 PS) / 92 lb⋅ft (125 N⋅m) 1989–1994 – 1.6 L (1,597 cc) B6, carburetor, 16-valve, SOHC, 103 hp (77 kW; 104 PS) / 108 lb⋅ft (146 N⋅m) 1989–1994 – 1.8 L (1,839 cc) BP, FI, 16-valve DOHC, 140 hp (104 kW; 142 PS) / 118 lb⋅ft (160 N⋅m) 1989–1994 – 1.8 L (1,839 cc) BPT, FI, 16-valve DOHC, turbo, 180 PS (132 kW) / 237 N⋅m (175 lb⋅ft) (Familia GT-X) 1991–1994 – 1.8 L (1,839 cc) B8, FI, 16-valve SOHC, 103 hp (77 kW) 1992–1993 – 1.8 L (1,839 cc) BPD, FI, 16-valve DOHC, turbo, 210 PS (154 kW) / 255 N⋅m (188 lb⋅ft) (Familia GT-R & GT-Ae) 1989–1994 – 1.7 L (1,720 cc) PN, Diesel, 8-valve, 57 PS (42 kW) / 112 N⋅m (83 lb⋅ft) (European specs)
Sources: en.wikipedia.org
Fukuyama congenital muscular dystrophy (FCMD) is a rare, autosomal recessive form of muscular dystrophy (weakness and breakdown of muscular tissue) mainly described in Japan but also identified in Turkish and Ashkenazi Jewish patients; fifteen cases were first described on 1960 by Dr. Yukio Fukuyama.FCMD mainly affects the brain, eyes, and muscles, in particular, the disorder affects development of the skeletal muscles leading to weakness and deformed appearances, and brain development is blunted affecting cognitive functioning as well as social skills. In 1995, the disorder was linked to mutations in a gene coding for the protein fukutin (the FCMD gene). Fukuyama congenital muscular dystrophy is the second most prevalent form of muscular dystrophy in Japan. One out of every 90 people in Japan is a heterozygous carrier.
=== Metric ounce === A metric ounce is an approximation of the imperial ounce, US dry ounce, or US fluid ounce. These three customary units vary. However, the metric ounce is usually taken as 25 or 30 ml (0.88 or 1.06 imp fl oz; 0.85 or 1.01 US fl oz) when volume is being measured, or in grams when mass is being measured. The US Food and Drug Administration (FDA) defines the "food labeling ounce" as 30.0 ml (1.06 imp fl oz; 1.01 US fl oz), slightly larger than the 29.6 ml (1.04 imp fl oz; 1.00 US fl oz) fluid ounce. Several Dutch units of measurement have been replaced with informal metric equivalents, including the ons or ounce. It originally meant 1⁄16 of a pound, or a little over 30 g (1.1 oz) depending on which definition of the pound was used, but was redefined as 100 g (3.5 oz) when the country metricated.
=== Physical symptoms === A low body mass index (BMI) for one's age and height (except in cases of atypical anorexia) Rapid, continuous weight loss Dry hair and skin, hair thinning, as well as hair loss Low body temperature (hypothermia) Raynaud Phenomenon Hypotension or orthostatic hypotension Bradycardia or tachycardia Chronic fatigue Insomnia Severe muscle tension, aches and pains Irregular or absent menstrual periods in women Infertility Gastrointestinal disease Halitosis (from vomiting or starvation-induced ketosis) Abdominal distension Russell's Sign; can be a tell-tale sign of self-induced vomiting with scratches on the back of the hand Tooth erosion Lanugo: soft, fine hair growing over the face and body Orange discoloration of the skin, particularly the feet (carotenosis)
== Pace-of-play initiatives == As a part of pace-of-play initiatives implemented in 2015, 20-second pitch clocks entered use at Double-A stadiums in 2015. In 2018, the time was shortened to 15 seconds when no runners are on base. Other significant changes implemented in 2018 included beginning extra innings with a runner on second base and limiting teams to eight mound visits during a nine-inning game. In 2019, the number of mound visits was reduced to seven, and pitchers were required to face a minimum of three consecutive batters, unless the side is retired or the pitcher is injured and unable to continue.
Sources: en.wikipedia.org
=== Personal motto === "With united forces" (as the Emperor of Austria) – German: "Mit vereinten Kräften" – Latin: "Viribus Unitis" "My trust in [the ancient] virtue" (as the Apostolic King of Hungary) – Hungarian: "Bizalmam az Ősi Erényben" – Latin: "Virtutis Confido"
Fe2O3 + 2 Al → 2 Fe + Al2O3 Alternatively pig iron may be made into steel (with up to about 2% carbon) or wrought iron (commercially pure iron). Various processes have been used for this, including finery forges, puddling furnaces, Bessemer converters, open hearth furnaces, basic oxygen furnaces, and electric arc furnaces. In all cases, the objective is to oxidize some or all of the carbon, together with other impurities. On the other hand, other metals may be added to make alloy steels.
Sydenham's chorea, also known as rheumatic chorea, is a disorder characterized by rapid, uncoordinated jerking movements primarily affecting the face, hands and feet. Sydenham's chorea is an autoimmune disease that results from childhood infection with Group A beta-haemolytic Streptococcus. It is reported to occur in 20–30% of people with acute rheumatic fever and is one of the major criteria for it, although it sometimes occurs in isolation. The disease occurs typically a few weeks, but up to 6 months, after the acute infection, which may have been a simple sore throat (pharyngitis). Sydenham's chorea is more common in females than males, and most cases affect children between 5 and 15 years of age. Adult onset of Sydenham's chorea is comparatively rare, and the majority of the adult cases are recurrences following childhood Sydenham's chorea (although pregnancy and female hormone treatment are also potential causes). It is historically one of the conditions called St Vitus' dance.
Activin and inhibin are two closely related protein complexes that have almost directly opposite biological effects. Identified in 1986, activin enhances FSH biosynthesis and secretion, and participates in the regulation of the menstrual cycle. Many other functions have been found to be exerted by activin, including roles in cell proliferation, differentiation, apoptosis, metabolism, homeostasis, immune response, wound repair, and endocrine function. Conversely, inhibin downregulates FSH synthesis and inhibits FSH secretion. The existence of inhibin was hypothesized as early as 1916; however, it was not demonstrated to exist until Neena Schwartz and Cornelia Channing's work in the mid-1970s, after which both proteins were molecularly characterized ten years later. Early in the process of its discovery, inhibin produced by the ovaries was also referred to as folliculostatin. Activin is a dimer composed of two identical or very similar beta subunits. Inhibin is also a dimer wherein the first component is a beta subunit similar or identical to the beta subunit in activin. However, in contrast to activin, the second component of the inhibin dimer is a more distantly-related alpha subunit. Activin, inhibin and a number of other structurally related proteins such as anti-Müllerian hormone, bone morphogenetic protein, and growth differentiation factor belong to the TGF-β protein superfamily.
== Veterinary uses == Eflornithine is effective in mice. Bacchi et al. 1980 found the drug to be curative in T. b. brucei infection of mouse and it is generally without toxicity. Klug et al. 2016 are of the opinion that this demonstrates good promise for oral treatment. However although Jansson et al. 2008 also effectively treated mice with it they found the pharmacokinetics of oral administration in rats very negative. Brun et al. 2010 are of the opinion that Jansson's results have killed the prospects for oral treatment.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.